Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Stem cell transplantation for primary immunodeficiencies the European experience

Stem cell transplantation for primary immunodeficiencies the European experience REVIEW URRENT Stem cell transplantation for primary PINION immunodeficiencies: the European experience a,b,c,d a,b,c,e c,e Marina Cavazzana , Fabien Touzot , Despina Moshous , c,e c,e c,d,e,f Be´ne´dicte Neven , Ste´phane Blanche , and Alain Fischer Purpose of review Primary immunodeficiencies (PIDs) constitute a heterogeneous group of inherited disorders affecting the development and/or function of the immune system. This review focuses on the recent advances in hematopoietic stem cell transplantation (HSCT) for PIDs, as it remains the only potentially curative option for many of these diseases. Recent findings We report on the most recent HSCT European results and suggest some opportunities for better treatment of certain PIDs. Progress on gene therapy is also discussed, as it emerges as an interesting option for PIDs management. Summary Progress in the treatment of primary immune deficiency with HSCT requires a better understanding of the pathophysiology and specificity of each of these diseases, allowing us to determine the best options in terms of donor, conditioning regimen, modification of the allograft and immunosuppressive therapy. Alternative therapies – such as gene therapy – emerge as an interesting option for some PIDs. Keywords gene therapy, hematopoietic stem cell transplantation, immunological reconstitution, primary immunodeficiencies INTRODUCTION SEVERE COMBINED http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Allergy and Clinical Immunology Wolters Kluwer Health

Stem cell transplantation for primary immunodeficiencies the European experience

Loading next page...
 
/lp/wolters-kluwer-health/stem-cell-transplantation-for-primary-immunodeficiencies-the-european-phQM2i0DLZ

References (44)

Copyright
© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
ISSN
1528-4050
eISSN
1473-6322
DOI
10.1097/ACI.0000000000000119
pmid
25304229
Publisher site
See Article on Publisher Site

Abstract

REVIEW URRENT Stem cell transplantation for primary PINION immunodeficiencies: the European experience a,b,c,d a,b,c,e c,e Marina Cavazzana , Fabien Touzot , Despina Moshous , c,e c,e c,d,e,f Be´ne´dicte Neven , Ste´phane Blanche , and Alain Fischer Purpose of review Primary immunodeficiencies (PIDs) constitute a heterogeneous group of inherited disorders affecting the development and/or function of the immune system. This review focuses on the recent advances in hematopoietic stem cell transplantation (HSCT) for PIDs, as it remains the only potentially curative option for many of these diseases. Recent findings We report on the most recent HSCT European results and suggest some opportunities for better treatment of certain PIDs. Progress on gene therapy is also discussed, as it emerges as an interesting option for PIDs management. Summary Progress in the treatment of primary immune deficiency with HSCT requires a better understanding of the pathophysiology and specificity of each of these diseases, allowing us to determine the best options in terms of donor, conditioning regimen, modification of the allograft and immunosuppressive therapy. Alternative therapies – such as gene therapy – emerge as an interesting option for some PIDs. Keywords gene therapy, hematopoietic stem cell transplantation, immunological reconstitution, primary immunodeficiencies INTRODUCTION SEVERE COMBINED

Journal

Current Opinion in Allergy and Clinical ImmunologyWolters Kluwer Health

Published: Dec 1, 2014

There are no references for this article.